WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory decisions
Fermer ce répertoireDrug surveillance
Afficher le documentAlbumin and plasma protein fraction - safety concerns: USA
Afficher le documentAlendronic acid - reminder: oesophageal reactions: UK
Afficher le documentDrug-induced amnesia - review: Australia
Afficher le documentIsotretinoin - depression: Australia
Afficher le documentIsotretinoin - adverse reaction profile: UK
Afficher le documentLeukotriene antagonists: montelukast & zafirlukast - safe use: UK
Afficher le documentLevonorgestrel - use for emergency contraception: WHO/HRP
Afficher le documentSelective serotonin reuptake inhibitors (SSRIs) - haemorrhage: Australia
Afficher le documentSildenafil (Viagra) - summary of reports of death: update: USA
Afficher le documentTryptophan, 5HTP and eosinophilia-myalgia syndrome - impurities confirmed: USA
Ouvrir ce répertoire et afficher son contenuNew developments
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Isotretinoin - depression: Australia

Australia. The Adverse Drug Reactions Advisory Committee has received a total of 129 reports of suspected adverse reactions in association with isotretinoin from 1985 to June 1998. Of these, 12 reports have described depression. All the patients involved were young (age range 15-40 years, median 19 years, M:F 9:3) and were taking the drug for the treatment of acne.

Two reports described the re-emergence of depression and in the other 10 reports depression was noted for the first time. Two cases were described as severe and 4 cases had psychotic features. Three patients developed suicidal thoughts and 2 patients attempted suicide. One of these had a fatal outcome. Of the other 11 patients, 3 had recovered after withdrawal of isotretinoin, one was improving with the use of an antidepressant, and the other 7 had not recovered at the time the report was submitted.

The product information for isotretinoin states that “depression has been reported in some patients on isotretinoin therapy”. The ADRAC urges prescribers to be alert for any adverse mood changes in their patients and to withdraw isotretinoin if these occur.

[See also Pharmaceuticals Newsletter Nos. 3&4, March & April 1998]

Reference: Australian Adverse Drug Reactions Bulletin 17(3): 11 (1998).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013